• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型喹诺酮类强效和选择性 HDAC6 抑制剂的合成、分子模拟研究及生物学研究。

Novel quinolone-based potent and selective HDAC6 inhibitors: Synthesis, molecular modeling studies and biological investigation.

机构信息

Department of Biotechnology, Chemistry and Pharmacy, DoE Department of Excellence 2018-2022, University of Siena, Via Aldo Moro 2, 53100, Siena, Italy.

Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126, Pisa, Italy.

出版信息

Eur J Med Chem. 2021 Feb 15;212:112998. doi: 10.1016/j.ejmech.2020.112998. Epub 2020 Nov 7.

DOI:10.1016/j.ejmech.2020.112998
PMID:33199154
Abstract

In this work we describe the synthesis of potent and selective quinolone-based histone deacetylase 6 (HDAC6) inhibitors. The quinolone moiety has been exploited as an innovative bioactive cap-group for HDAC6 inhibition; its synthesis was achieved by applying a multicomponent reaction. The optimization of potency and selectivity of these products was performed by employing computational studies which led to the discovery of the diethylaminomethyl derivatives 7g and 7k as the most promising hit molecules. These compounds were investigated in cellular studies to evaluate their anticancer effect against colon (HCT-116) and histiocytic lymphoma (U9347) cancer cells, showing good to excellent potency, leading to tumor cell death by apoptosis induction. The small molecules 7a, 7g and 7k were able to strongly inhibit the cytoplasmic and slightly the nuclear HDAC enzymes, increasing the acetylation of tubulin and of the lysine 9 and 14 of histone 3, respectively. Compound 7g was also able to increase Hsp90 acetylation levels in HCT-116 cells, thus further supporting its HDAC6 inhibitory profile. Cytotoxicity and mutagenicity assays of these molecules showed a safe profile; moreover, the HPLC analysis of compound 7k revealed good solubility and stability profile.

摘要

在这项工作中,我们描述了强效和选择性的基于喹诺酮的组蛋白去乙酰化酶 6(HDAC6)抑制剂的合成。喹诺酮部分被用作 HDAC6 抑制的创新生物活性帽基团;其合成是通过应用多组分反应来实现的。通过使用计算研究对这些产物的效力和选择性进行优化,发现二乙氨基甲基衍生物 7g 和 7k 是最有前途的命中分子。这些化合物在细胞研究中进行了评估,以研究它们对结肠癌(HCT-116)和组织细胞淋巴瘤(U9347)癌细胞的抗癌作用,显示出良好至优异的效力,通过诱导细胞凋亡导致肿瘤细胞死亡。小分子 7a、7g 和 7k 能够强烈抑制细胞质和稍微核 HDAC 酶,分别增加微管蛋白和组蛋白 3 的赖氨酸 9 和 14 的乙酰化。化合物 7g 还能够增加 HCT-116 细胞中 Hsp90 的乙酰化水平,从而进一步支持其 HDAC6 抑制作用。这些分子的细胞毒性和致突变性试验显示出安全的特性;此外,化合物 7k 的 HPLC 分析显示出良好的溶解度和稳定性特性。

相似文献

1
Novel quinolone-based potent and selective HDAC6 inhibitors: Synthesis, molecular modeling studies and biological investigation.新型喹诺酮类强效和选择性 HDAC6 抑制剂的合成、分子模拟研究及生物学研究。
Eur J Med Chem. 2021 Feb 15;212:112998. doi: 10.1016/j.ejmech.2020.112998. Epub 2020 Nov 7.
2
Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.四氢-β-咔啉衍生物的设计与生物评价:作为高效组蛋白去乙酰化酶 6(HDAC6)抑制剂。
Eur J Med Chem. 2018 May 25;152:329-357. doi: 10.1016/j.ejmech.2018.04.046. Epub 2018 Apr 26.
3
Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors.设计、合成及生物评价 3,4-二取代-咪唑烷-2,5-二酮衍生物作为 HDAC6 选择性抑制剂。
Eur J Med Chem. 2021 Oct 5;221:113526. doi: 10.1016/j.ejmech.2021.113526. Epub 2021 May 7.
4
Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity.开发具有体外和体内抗多发性骨髓瘤活性的选择性 HDAC6 抑制剂。
Bioorg Chem. 2021 Nov;116:105278. doi: 10.1016/j.bioorg.2021.105278. Epub 2021 Aug 19.
5
Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.基于吩噻嗪的苯甲羟肟酸的合成与生物研究作为选择性组蛋白去乙酰化酶 6 抑制剂。
J Med Chem. 2019 Feb 14;62(3):1138-1166. doi: 10.1021/acs.jmedchem.8b01090. Epub 2019 Feb 1.
6
Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies.新型螺环吲哚啉 HDAC 抑制剂的合成、分子模拟及生物学研究。
Eur J Med Chem. 2018 Sep 5;157:127-138. doi: 10.1016/j.ejmech.2018.07.069. Epub 2018 Jul 31.
7
The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.组蛋白去乙酰化酶抑制剂的结构要求:C4修饰的SAHA类似物具有HDAC6/HDAC8双重选择性。
Eur J Med Chem. 2018 Jan 1;143:1790-1806. doi: 10.1016/j.ejmech.2017.10.076. Epub 2017 Oct 31.
8
Inhibitors of histone deacetylase 6 based on a novel 3-hydroxy-isoxazole zinc binding group.基于新型 3-羟基异恶唑锌结合基团的组蛋白去乙酰化酶 6 抑制剂。
J Enzyme Inhib Med Chem. 2021 Dec;36(1):2080-2086. doi: 10.1080/14756366.2021.1981306.
9
Novel pyrrolo[2,1-c][1,4]benzodiazepine-3,11-dione (PBD) derivatives as selective HDAC6 inhibitors to suppress tumor metastasis and invasion in vitro and in vivo.新型吡咯并[2,1-c][1,4]苯并二氮杂卓-3,11-二酮(PBD)衍生物作为选择性 HDAC6 抑制剂,抑制肿瘤转移和侵袭的体外和体内研究。
Bioorg Chem. 2021 Sep;114:105081. doi: 10.1016/j.bioorg.2021.105081. Epub 2021 Jun 11.
10
Enantioselective synthesis and biological investigation of tetrahydro-β-carboline-based HDAC6 inhibitors with improved solubility.基于四氢-β-咔啉的 HDAC6 抑制剂的对映选择性合成及生物研究:溶解度的改善。
Arch Pharm (Weinheim). 2019 Jun;352(6):e1900026. doi: 10.1002/ardp.201900026. Epub 2019 May 6.

引用本文的文献

1
Spirotetrahydroisoquinoline-Based Histone Deacetylase Inhibitors as New Antifibrotic Agents: Biological Evaluation in Human Fibroblasts from Bronchoalveolar Lavages of Idiopathic Pulmonary Fibrosis Patients.基于螺环四氢异喹啉的组蛋白去乙酰化酶抑制剂作为新型抗纤维化药物:对特发性肺纤维化患者支气管肺泡灌洗来源的人成纤维细胞的生物学评价
ACS Pharmacol Transl Sci. 2024 Nov 12;8(2):380-393. doi: 10.1021/acsptsci.4c00456. eCollection 2025 Feb 14.
2
The Histone Deacetylase Family: Structural Features and Application of Combined Computational Methods.组蛋白去乙酰化酶家族:结构特征及联合计算方法的应用
Pharmaceuticals (Basel). 2024 May 10;17(5):620. doi: 10.3390/ph17050620.
3
Quinolone Derivatives as Anticancer Agents: Importance in Medicinal Chemistry.
喹诺酮衍生物作为抗癌剂:在药物化学中的重要性。
Curr Top Med Chem. 2024;24(13):1134-1157. doi: 10.2174/0115680266300736240403075307.
4
Effects of structurally distinct human HDAC6 and HDAC6/HDAC8 inhibitors against S. mansoni larval and adult worm stages.结构不同的人类HDAC6和HDAC6/HDAC8抑制剂对曼氏血吸虫幼虫和成虫阶段的影响。
PLoS Negl Trop Dis. 2024 Feb 28;18(2):e0011992. doi: 10.1371/journal.pntd.0011992. eCollection 2024 Feb.
5
Heterocyclic Compounds as Hsp90 Inhibitors: A Perspective on Anticancer Applications.作为Hsp90抑制剂的杂环化合物:抗癌应用前景
Pharmaceutics. 2022 Oct 18;14(10):2220. doi: 10.3390/pharmaceutics14102220.
6
A Therapeutic Perspective of HDAC8 in Different Diseases: An Overview of Selective Inhibitors.HDAC8 在不同疾病中的治疗视角:选择性抑制剂概述。
Int J Mol Sci. 2022 Sep 2;23(17):10014. doi: 10.3390/ijms231710014.
7
HDAC6: A unique HDAC family member as a cancer target.HDAC6:作为癌症靶点的独特 HDAC 家族成员。
Cell Oncol (Dordr). 2022 Oct;45(5):779-829. doi: 10.1007/s13402-022-00704-6. Epub 2022 Aug 29.
8
Design and Synthesis of New Pyrimidine-Quinolone Hybrids as Novel LDHA Inhibitors.新型嘧啶-喹诺酮杂合物作为新型乳酸脱氢酶A(LDHA)抑制剂的设计与合成
Pharmaceuticals (Basel). 2022 Jun 24;15(7):792. doi: 10.3390/ph15070792.
9
Rational design of synthetically tractable HDAC6/HSP90 dual inhibitors to destroy immune-suppressive tumor microenvironment.合理设计可综合的 HDAC6/HSP90 双重抑制剂以破坏免疫抑制性肿瘤微环境。
J Adv Res. 2023 Apr;46:159-171. doi: 10.1016/j.jare.2022.06.009. Epub 2022 Jun 22.
10
Harnessing the Role of HDAC6 in Idiopathic Pulmonary Fibrosis: Design, Synthesis, Structural Analysis, and Biological Evaluation of Potent Inhibitors.利用组蛋白去乙酰化酶 6 在特发性肺纤维化中的作用:有效抑制剂的设计、合成、结构分析和生物学评价。
J Med Chem. 2021 Jul 22;64(14):9960-9988. doi: 10.1021/acs.jmedchem.1c00184. Epub 2021 Jul 12.